NASDAQ:GMDA - Gamida Cell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gamida Cell Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.64 +0.07 (+1.53 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$4.61Now: $4.64▼$4.6550-Day Range$4.30MA: $4.62▼$5.1052-Week Range$2.93Now: $4.64▼$15.00Volume15,899 shsAverage Volume29,694 shsMarket Capitalization$112.39 millionP/E RatioN/ADividend YieldN/ABeta1.64 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMDA Previous Symbol CUSIPN/A CIKN/A Webhttp://www.gamida-cell.com/ Phone972-2659-5666Debt Debt-to-Equity Ratio0.09 Current Ratio7.61 Quick Ratio7.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book4.55Profitability EPS (Most Recent Fiscal Year)($10.53) Net Income$-52,930,000.00 Net MarginsN/A Return on Equity-215.37% Return on Assets-89.08%Miscellaneous Employees70 Outstanding Shares24,222,000Market Cap$112.39 million Next Earnings Date2/24/2020 (Estimated) OptionableNot Optionable Receive GMDA News and Ratings via Email Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GMDA Rates by TradingView Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions What is Gamida Cell's stock symbol? Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA." How were Gamida Cell's earnings last quarter? Gamida Cell Ltd (NASDAQ:GMDA) issued its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.37) by $0.07. View Gamida Cell's Earnings History. When is Gamida Cell's next earnings date? Gamida Cell is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Gamida Cell. What price target have analysts set for GMDA? 3 Wall Street analysts have issued 1-year price objectives for Gamida Cell's shares. Their forecasts range from $16.00 to $19.00. On average, they expect Gamida Cell's share price to reach $17.67 in the next year. This suggests a possible upside of 280.7% from the stock's current price. View Analyst Price Targets for Gamida Cell. What is the consensus analysts' recommendation for Gamida Cell? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell. Has Gamida Cell been receiving favorable news coverage? Press coverage about GMDA stock has been trending very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gamida Cell earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the near term. View News Stories for Gamida Cell. Are investors shorting Gamida Cell? Gamida Cell saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,200 shares, a drop of 84.0% from the December 15th total of 7,500 shares. Based on an average daily trading volume, of 36,900 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's stock are sold short. View Gamida Cell's Current Options Chain. Who are some of Gamida Cell's key competitors? Some companies that are related to Gamida Cell include Verona Pharma (TARA), BioCryst Pharmaceuticals (BCRX), Adaptimmune Therapeutics (ADAP), Cabaletta Bio (CABA), Harpoon Therapeutics (HARP), PDL BioPharma (PDLI), Gritstone Oncology (GRTS), Compugen (CGEN), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), Tcr2 Therapeutics (TCRR), Scholar Rock (SRRK), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA) and Sutro Biopharma (STRO). What other stocks do shareholders of Gamida Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Palatin Technologies (PTN), Cisco Systems (CSCO), LYFT (LYFT), Outlook Therapeutics (OTLK), Ovid Therapeutics (OVID), People's United Financial (PBCT), PhaseBio Pharmaceuticals (PHAS), Spring Bank Pharmaceuticals (SBPH), Sorrento Therapeutics (SRNE) and ONEOK (OKE). Who are Gamida Cell's key executives? Gamida Cell's management team includes the folowing people: Julian Adams, Chief Executive Officer & DirectorYael Margolin, PresidentTzvi Palash, Chief Operating OfficerShai Lankry, Chief Financial & Accounting OfficerTony Peled, Chief Scientific Officer, Vice President-R&D When did Gamida Cell IPO? (GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager. How do I buy shares of Gamida Cell? Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Gamida Cell's stock price today? One share of GMDA stock can currently be purchased for approximately $4.64. How big of a company is Gamida Cell? Gamida Cell has a market capitalization of $112.39 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell. What is Gamida Cell's official website? The official website for Gamida Cell is http://www.gamida-cell.com/. How can I contact Gamida Cell? Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected] MarketBeat Community Rating for Gamida Cell (NASDAQ GMDA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 62 (Vote Outperform)Underperform Votes: 62 (Vote Underperform)Total Votes: 124MarketBeat's community ratings are surveys of what our community members think about Gamida Cell and other stocks. Vote "Outperform" if you believe GMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: What is a death cross?
